{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/04/21/3278175/0/en/Black-Diamond-Therapeutics-Announces-Oral-Presentation-of-Silevertinib-Phase-2-Data-in-Frontline-EGFRm-NSCLC-Patients-at-the-2026-ASCO-Annual-Meeting.html", "message": "News view counter 673613 successfully enlarged"}